Drug Profile
Research programme: nanomedicine diagnostics and therapeutics - Akrivis Technologies/CEA-Leti
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Akrivis Technologies; CEA-LETI
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Undefined(Diagnosis) in France
- 19 Jun 2014 Early research in Undefined indication (diagnosis) in France (unspecified route)